All lobbying filings
BGR Government Affairs
BGR Government Affairs filed a Q3 report for Fresenius Medical Care North America (FKA Fresenius Medical Care) on October 20, 2026, reporting $90,000 in lobbying income.
Lobbying for Fresenius Medical Care North America (FKA Fresenius Medical Care)
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$90,000
What the client paid this registrant for the period.
Lobbyists on this filing
8
-
ROBERT WOODPreviously held: Chief of Staff to HHS Secretary; Intern to Rep. Scott Klug
-
JENNIFER LARKIN LUKAWSKIPreviously held: Leg. Dir. Rep. Dornan, Ex. Dir., U.S. House Con. Act. Team (Rep. Study Comm.); Intern, Staff Asst. Rep. Courter
-
ROBB WALTONPreviously held: Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes
-
DANIEL FARMERPreviously held: Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space
-
RAGHAV AGGARWALPreviously held: Health Insurance Specialist, CMS; Senior Health Advisor (Detailee), Senate Finance Committee/Sen. Ron Wyden; Social Science Research Analyst, CMS; Intern, Sen. Feinstein; Secretarys Fellow, US Dept. of Interior
-
REMY LEIGH BRIM MASONPreviously held: Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz
-
CHARLES FLETCHER CHAPMANPreviously held: Policy Advisor, HHS; Special Asst, HHS; Prof Staff Member, House Budget Committee; LA, House Budget Committee; Staff Asst, House Ways and Means Committee; Intern, House Ways and Means Committee
-
JOHN STONEPreviously held: Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C
Government bodies contacted
4
Lobbying activity
1
Medicare reimbursement; End stage renal disease (ESRD) payment reforms; extension of Medicare sequester; telehealth policy and waivers; issues pertaining to Medicare Secondary Payer Act; oral-only ESRD drugs